(Q46039809)

18 December 2017

title

Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. (English)

1 reference

18 December 2017

0 references

1 reference

6

Toru Takebayashi

1 reference

18 December 2017

author name string

Tatsuhiko Yagihashi

1

1 reference

18 December 2017

Masafumi Mizuno

2

1 reference

18 December 2017

Bun Chino

3

1 reference

18 December 2017

Yuji Sato

4

1 reference

18 December 2017

Kei Sakuma

5

1 reference

18 December 2017

Takahashi Takao

7

1 reference

18 December 2017

Kenjiro Kosaki

8

1 reference

18 December 2017

publication date

1 June 2009

1 reference

18 December 2017

published in

Human Psychopharmacology

1 reference

18 December 2017

volume

24

1 reference

18 December 2017

issue

4

1 reference

18 December 2017

page(s)

301-308

1 reference

18 December 2017

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects

cites work

1 reference

Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors.

21 January 2018

1 reference

7 January 2021

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs

1 reference

7 January 2021

Cytochrome P450 enzymes contributing to demethylation of maprotiline in man.

1 reference

7 January 2021

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

1 reference

7 January 2021

Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline

1 reference

7 January 2021

Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes

1 reference

7 January 2021

Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia.

1 reference

7 January 2021

The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation

1 reference

7 January 2021

A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.

1 reference

7 January 2021

An evaluation of risperidone drug interactions

1 reference

7 January 2021

Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4

1 reference

7 January 2021

Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity

1 reference

7 January 2021

The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6.

1 reference

7 January 2021

Influence of fluoxetine on olanzapine pharmacokinetics

1 reference

7 January 2021

Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes: prediction of in vivo drug interactions.

1 reference

7 January 2021

AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping.

1 reference

7 January 2021

No association between CYP2D6 polymorphisms and personality trait in Japanese

1 reference

7 January 2021

Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions.

1 reference

7 January 2021

The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6

1 reference

7 January 2021

Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia

1 reference

7 January 2021

Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents

1 reference

7 January 2021

Thioridazine inhibits risperidone metabolism: a clinically relevant drug interaction

1 reference

7 January 2021

Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.

1 reference

7 January 2021

D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients.

1 reference

7 January 2021

Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry

1 reference

7 January 2021

Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients

1 reference

7 January 2021

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

1 reference

7 January 2021

Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine

1 reference

7 January 2021

Debrisoquine oxidation phenotype during neuroleptic monotherapy

1 reference

7 January 2021

Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine

1 reference

7 January 2021

Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol

1 reference

7 January 2021

Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population

1 reference

7 January 2021

The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein

1 reference

7 January 2021

Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects

1 reference

7 January 2021

Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms

1 reference

7 January 2021

Identifiers

DOI

10.1002/HUP.1025

1 reference

18 December 2017

1 reference

18 December 2017